Direct mailing to about 22,000 pharmacists highlights "no need for patients to refrigerate" the estrogen/progestin patch. Combipatch should be kept refrigerated prior to dispensing, Novogyne said. The Novartis/Noven joint venture is re-launching Combipatch, approved in August 1998, with its 120-rep sales force. Novogyne acquired the product from Aventis in March for about $65 mil
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth